MA30086B1 - 3-ALKYLAZETIDINE DERIVATIVES HETEROCYCLIC SUBSTITUENTS. - Google Patents
3-ALKYLAZETIDINE DERIVATIVES HETEROCYCLIC SUBSTITUENTS.Info
- Publication number
- MA30086B1 MA30086B1 MA31075A MA31075A MA30086B1 MA 30086 B1 MA30086 B1 MA 30086B1 MA 31075 A MA31075 A MA 31075A MA 31075 A MA31075 A MA 31075A MA 30086 B1 MA30086 B1 MA 30086B1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- disorders
- useful
- compounds
- disease
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 abstract 1
- 206010010774 Constipation Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 206010014612 Encephalitis viral Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010019196 Head injury Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000014797 chronic intestinal pseudoobstruction Diseases 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 201000002498 viral encephalitis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Les nouveaux composés de formule développée (I) sont des antagonistes et/ou agonistes inverses du récepteur des cannabinoïdes-1 (CB1) et sont utiles dans le traitement, la prévention et la suppression des maladies régulées par le récepteur CB1. Les composés de la présente invention sont utiles comme médicaments actifs agissant de manière centrale dans le traitement des psychose, insuffisances de mémoire, troubles cognitifs, maladie d'Alzheimer, migraine, neuropathie, troubles neuro-inflammatoires y compris sclérose en plaques et syndrome de Guillain-Barre et les séquelles inflammatoires de l'encéphalite virale, accidents cérébraux vasculaires, et traumatisme crânien, troubles de l'anxiété, stress, épilepsie, maladie de Parkinson, troubles du mouvement, et schizophrénie. Les composés sont aussi utiles pour le traitement des troubles d'abus de substances, le traitement de l'obésité ou des troubles de l'alimentation, ainsi que le traitement de l'asthme, la constipation, la pseudo-obstruction intestinale chronique, et la cirrhose du foie.The novel compounds of structural formula (I) are antagonists and / or inverse agonists of the cannabinoid-1 receptor (CB1) and are useful in the treatment, prevention and suppression of CB1 receptor mediated diseases. The compounds of the present invention are useful as active drugs acting centrally in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuroinflammatory disorders including multiple sclerosis and Guillain's syndrome. -Barre and inflammatory sequelae of viral encephalitis, cerebrovascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74018305P | 2005-11-28 | 2005-11-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA30086B1 true MA30086B1 (en) | 2008-12-01 |
Family
ID=37779312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA31075A MA30086B1 (en) | 2005-11-28 | 2008-06-25 | 3-ALKYLAZETIDINE DERIVATIVES HETEROCYCLIC SUBSTITUENTS. |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1954692A1 (en) |
| KR (1) | KR20080073721A (en) |
| AR (1) | AR058199A1 (en) |
| BR (1) | BRPI0619018A2 (en) |
| CR (1) | CR10014A (en) |
| DO (1) | DOP2006000261A (en) |
| EC (1) | ECSP088477A (en) |
| IL (1) | IL191586A0 (en) |
| MA (1) | MA30086B1 (en) |
| NO (1) | NO20082919L (en) |
| PE (1) | PE20070647A1 (en) |
| RU (1) | RU2008126248A (en) |
| SV (1) | SV2009002917A (en) |
| TW (1) | TW200804317A (en) |
| WO (1) | WO2007062193A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7906652B2 (en) | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
| EP2025674A1 (en) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs |
| AU2008317482A1 (en) * | 2007-10-24 | 2009-04-30 | Merck Sharp & Dohme Corp. | Synthesis and crystalline forms of CB-1 antagonist/inverse agonist |
| WO2012031220A2 (en) | 2010-09-03 | 2012-03-08 | University Of Florida Research Foundation, Inc. | Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use |
| WO2012120053A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120056A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| WO2012120052A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2805818B1 (en) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| FR2805810B1 (en) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | PHARMACEUTICAL COMPOSITIONS CONTAINING 3- AMINO-AZETIDINE DERIVATIVES, THE NEW DERIVATIVES AND THEIR PREPARATION |
| FR2805817B1 (en) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND THEIR PREPARATION |
| CN1802351A (en) * | 2003-06-11 | 2006-07-12 | 麦克公司 | Substituted 3-alkyl and 3-alkenyl azetidine derivatives |
| AU2006242219A1 (en) * | 2005-05-02 | 2006-11-09 | Merck & Co., Inc. | Combination of dipeptidyl peptidase-IV inhibitor and a cannabinoid CB1 receptor antagonist for the treatment of diabetes and obesity |
-
2006
- 2006-11-20 AR ARP060105076A patent/AR058199A1/en unknown
- 2006-11-22 KR KR1020087012880A patent/KR20080073721A/en not_active Withdrawn
- 2006-11-22 TW TW095143274A patent/TW200804317A/en unknown
- 2006-11-22 BR BRPI0619018A patent/BRPI0619018A2/en not_active IP Right Cessation
- 2006-11-22 EP EP06838347A patent/EP1954692A1/en not_active Withdrawn
- 2006-11-22 WO PCT/US2006/045328 patent/WO2007062193A1/en not_active Ceased
- 2006-11-22 RU RU2008126248/04A patent/RU2008126248A/en not_active Application Discontinuation
- 2006-11-23 PE PE2006001495A patent/PE20070647A1/en not_active Application Discontinuation
- 2006-11-23 DO DO2006000261A patent/DOP2006000261A/en unknown
-
2008
- 2008-05-20 IL IL191586A patent/IL191586A0/en unknown
- 2008-05-22 CR CR10014A patent/CR10014A/en not_active Application Discontinuation
- 2008-05-27 EC EC2008008477A patent/ECSP088477A/en unknown
- 2008-05-28 SV SV2008002917A patent/SV2009002917A/en not_active Application Discontinuation
- 2008-06-25 MA MA31075A patent/MA30086B1/en unknown
- 2008-06-27 NO NO20082919A patent/NO20082919L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20082919L (en) | 2008-08-27 |
| RU2008126248A (en) | 2010-01-10 |
| IL191586A0 (en) | 2008-12-29 |
| AR058199A1 (en) | 2008-01-23 |
| PE20070647A1 (en) | 2007-08-11 |
| TW200804317A (en) | 2008-01-16 |
| CR10014A (en) | 2008-07-29 |
| KR20080073721A (en) | 2008-08-11 |
| BRPI0619018A2 (en) | 2016-11-29 |
| EP1954692A1 (en) | 2008-08-13 |
| ECSP088477A (en) | 2008-06-30 |
| SV2009002917A (en) | 2009-02-19 |
| DOP2006000261A (en) | 2007-07-15 |
| WO2007062193A1 (en) | 2007-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA27847A1 (en) | AZETIDINE DERIVATIVES SUBSTITUTED WITH 3-ALKYL AND 3-ALKENYL. | |
| MA30086B1 (en) | 3-ALKYLAZETIDINE DERIVATIVES HETEROCYCLIC SUBSTITUENTS. | |
| DE60334787D1 (en) | SUBSTITUTED AMIDE | |
| MY134457A (en) | Substituted amides | |
| DE60316829D1 (en) | SUBSTITUTED FUROÄ2,3-BÜPYRIDINE DERIVATIVES | |
| EP1492784A4 (en) | 2,3-DIPHENYL-PYRIDINES SUBSTITUTED | |
| WO2003086288A3 (en) | Bicyclic amides | |
| WO2004058145A3 (en) | Substituted amides | |
| WO2004029204A3 (en) | Substituted pyrimidines | |
| DE602004024814D1 (en) | SUBSTITUTED NAPHTHYRIDINONE DERIVATIVES | |
| WO2003082190A3 (en) | Spirocyclic amides as cannabinoid receptor modulators | |
| WO2003063781A3 (en) | Substituted imidazoles as cannabinoid receptor modulators | |
| WO2003007887A3 (en) | Substituted imidazoles as cannabinoid receptor modulators | |
| WO2008024284A3 (en) | Sulfonylated piperazines as cannabinoid-1 receptor modulators | |
| ATE501151T1 (en) | SUBSTITUTED PYRANO Ä2, 3 - BUPYRIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | |
| NO20063381L (en) | CB1 modulator connections | |
| WO2007136607A3 (en) | Substituted esters as cannabinoid-1 receptor modulators | |
| US20190389865A1 (en) | SUBSTITUTED PYRROLO[1,2-a]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | |
| DE602004024188D1 (en) | THE OPIOID RECEPTOR | |
| ATE457985T1 (en) | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS MEDICINAL PRODUCTS | |
| CA2522323A1 (en) | 3-azabicyclo[3.2.1]octane derivatives as opioid receptor ligands | |
| WO2007064566A3 (en) | Heterocycle-substituted 3-alkyl azetidine derivatives | |
| IL192240A0 (en) | Substituted pyrazinone derivatives as alpha2c-adrenoreceptor antagonists | |
| WO2006041797A3 (en) | Acyclic hydrazides as cannabinoid receptor modulators | |
| ATE471322T1 (en) | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS MEDICINAL PRODUCTS |